Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2017Journal of Oncology Pharmacy Practice

Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Do DOACs provide similar safety and efficacy compared to LMWH and warfarin for VTE treatment in patients with cancer?

Population

131 patients with cancer and venous thromboembolism (VTE) in an urban university setting

Comparison

Direct oral anticoagulants (DOACs) vs Low molecular weight heparin (LMWH) and warfarin

Design

Cohort

Authors

EUEllen M. UppuluriKBKelly R BurkeCHChristina Haaf

Discussion

Loading...

Member takes

Overview

Supports DOACs as a reasonable alternative for cancer-associated VTE; leaves open.

Structured PICO

Do DOACs provide similar safety and efficacy compared to LMWH and warfarin for VTE treatment in patients with cancer?

P
Population
131 patients with cancer and venous thromboembolism (VTE) in an urban university setting
I
Intervention
Direct oral anticoagulants (DOACs)
C
Comparator
Low molecular weight heparin (LMWH) and warfarin
O
Outcome
Recurrence of VTE and number of bleeding eventshard clinical

DOACs may be as safe and effective as LMWH and warfarin for VTE treatment in cancer patients, and routine anti-Xa monitoring for LMWH may not provide clinical benefit.

Limitations

  • Small sample size requiring larger studies to confirm observations
  • Retrospective design

Cite This Study

Uppuluri et al. (2017) studied this question.

synapsesocial.com/papers/6a85593a37bcb8373dad9974https://doi.org/10.1177/1078155217730129
View Full Paper
Ask AI
Bookmark
Share